Breaking News, Collaborations & Alliances

Marvel Biotechnology Begins cGMP Manufacturing of Lead Candidate

Enters manufacturing agreement with Ausun Pharma for lead asset MB-204.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Marvel Biotechnology has reported a milestone in the development of its lead compound MB-204, entering into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical. The partnership is for the supply of Marvel’s lead asset MB-204 for toxicology studies and clinical trials. MB-204 has potential application for the treatment of depression and anxiety, Alzheimer’s, ADHD and non-neurological diseases such as cancer and non-alcoholic steatohepatitis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters